Comment on

• Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.

  Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Paleolog EM, et al. Arthritis Rheum. 1996 Jul;39(7):1082-91. doi: 10.1002/art.1780390703. Arthritis Rheum. 1996. PMID: 8670315 Clinical Trial.
• Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

  Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN. Taylor PC, et al. Arthritis Rheum. 2000 Jan;43(1):38-47. doi: 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L. Arthritis Rheum. 2000. PMID: 10643698
• Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.

  Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, De Vos M, Mielants H, Veys EM, De Keyser F. Baeten D, et al. Arthritis Rheum. 2001 Jan;44(1):186-95. doi: 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B. Arthritis Rheum. 2001. PMID: 11212159